BJH - volume 9, issue 4, august 2018
A. De Becker MD
The treatment modalities in the field of acute leukemia have seen spectacular changes in recent years. The introduction of chimeric antigen receptor T-cells (CAR T-cells) and bispecific T-cell engagers (BiTEs) dramatically improved the outcome of heavily pretreated patients with B-cell acute lymphoblastic leukemia (B-ALL). For the treatment of acute myeloid leukemia (AML), immunotherapy is more difficult to design, but also in this setting progress has been made. This text will describe recent advances in the field of acute leukemia presented at the latest EHA meeting.
(BELG J HEMATOL 2018;9(4):148–51)
Read moreBJH - volume 9, issue 4, august 2018
T. Feys MBA, MSc
EHA 2018 featured several eagerly awaited presentations on Hodgkin lymphoma. This included subgroup data of the ECHELON-1 trial in patients with high-risk features and data of a PET-based treatment de-escalation study. In non-Hodgkin lymphoma, the RELEVANCE study assessed the chemotherapy-free lenalidomide-rituximab combination as 1st line treatment for follicular lymphoma. In diffuse-large-B-cell lymphoma, updates were presented of the key studies evaluating CAR T-cell therapy and polatuzumab vedotin was found to improve the survival in relapsed/refractory patients.
(BELG J HEMATOL 2018;9(4):152–6)
Read moreBJH - volume 9, issue 4, august 2018
B. Heyrman MD
Novel therapeutic options for patients suffering from myelodysplastic syndromes (MDS) have not managed to climb the stage in recent years. However, clinical trials with new agents were ongoing under the radar. During the 2018 annual EHA meeting, new results were presented that may be inspiring for new clinical trials leading to drug approvals and the expansion of our therapeutic arsenal in this difficult-to-treat patient population. In addition to MDS, this overview will also address the key data on myeloproliferative diseases presented at EHA 2018.
(BELG J HEMATOL 2018;9(4):157–60)
Read moreBJH - volume 9, issue 4, august 2018
B. Gulbis MD, PhD
Red blood cell pathologies were highlighted during the congress. In particular, the Topics-in-Focus program put the spotlight on haemoglobinopathies. As in oncology, these heterogeneous (very) rare diseases also benefit from new tools for their diagnosis and from new or evolving therapies. Gene therapy is probably the most exciting one as it represents a curative approach.
(BELG J HEMATOL 2018;9(4):161–3)
Read moreBJH - volume 9, issue 1, february 2018
R. Schots MD, PhD
The selection for this best of ASH article was based on the studies that were selected for presentation during the presidential symposium, the late breaking abstract session and the “best of ASH” session at the 2017 annual meeting of the American Society of Hematology (ASH). The selection is primarily targeted at clinicians and the information from these sessions was grouped into 5 chapters: studies likely to have an impact on our clinical practice on the short term, early clinical trials with promising new treatments, therapeutic advances in rare hematological diseases, new insights in mechanisms of disease and innovative applications for next generation sequencing (NGS).
(BELG J HEMATOL 2018;9(1):3–7)
Read moreBJH - volume 9, issue 1, february 2018
No authors
With more than 900 abstracts focusing on multiple myeloma (MM), the 2017 annual meeting of the American Society of Hematology (ASH) shows once more the great interest of the myeloma community in identifying new potential targets and developing novel therapeutic strategies for this devastating disease.
(BELG J HEMATOL 2018;9(1):8–11)
Read moreBJH - volume 9, issue 1, february 2018
S. Snauwaert MD, PhD
This non-comprehensive summary of abstracts dedicated to lymphoma that were presented at ASH 2017, will focus on Hodgkin lymphoma (HL), follicular lymphoma (FL), primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL). Although this selection of abstracts is of course biased by personal interest, it aims to give you a relevant overview for daily clinical practice.
(BELG J HEMATOL 2018;9(1):14–8)
Read more
Top
